

Resources

- [Canvas](#)
- [Duke Hub](#)
- [Program Website](#)
- [Application Website](#)

Class Links

Tuesday Classes

- [CRP 271, 13:30 - 15:00](#)
- [CRP 248, 15:15 - 16:30](#)

Thursday Classes

- [CRP 254](#)
- [CRP 245](#)

Deadlines, CRP 248

Project

Factor XIa Inhibition (Abelacimab) for ECMO and Mechanical Support

- The Drug:
 - Abelacimab (a novel Factor XIa inhibitor).
- The Concept:
 - A Phase 3 trial evaluating whether a Factor XIa inhibitor reduces circuit thrombosis and bleeding compared to standard unfractionated heparin in patients on mechanical circulatory support.

date	item
2026-10-27	LOI for phase II or III trial
2026-12-01	10-minute presentation of the LOI
2026-12-08	take-home exam due

From:

<https://ewrobbins.com/> - ewrobbins.com

Permanent link:

<https://ewrobbins.com/doku.php?id=duke&rev=1790104454>

Last update: **2026/09/22 19:14**

